Skip to content

Bone Remodeling Around a Trabecular Titanium Cup in Total Hip Arthroplasty

Bone Remodeling Around a 3D-printed Highly-porous Trabecular Titanium Acetabular Cup in Primary Total Hip Arthroplasty

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06287021
Enrollment
50
Registered
2024-02-29
Start date
2024-04-09
Completion date
2028-06-30
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty

Keywords

Bone Mineral Density, DEXA, Additive Manufacturing, 3D-Printing, Selective Laser Melting, Highly-Porous Titanium

Brief summary

The goal of this randomized controlled trial is to measure the periprosthetic bone mineral density changes around a 3D-printed highly-porous titanium acetabular cup used in primary total hip arthroplasty compared to a standard hydroxyapatite/titanium plasma-sprayed acetabular cup up to 2-year follow-up.

Detailed description

In joint arthroplasty, the need to use devices with highly-porous structures even more close to cancellous bone, arises from the need of optimal implant primary stability and osseointegration to guarantee long term longevity of the prosthetic implant. After decades of clinical use of highly-porous tantalum (Trabecular Metal) acetabular components in total hip arthroplasty with excellent results, new highly-porous titanium structures have been developed and introduced in the market thanks to the additive manufacturing technology. This study aims to investigate how bone remodeling occurs after primary total hip arthroplasty around a highly-porous trabecular-irregular acetabular cup, 3D-printed with selective laser melting, in comparison with a standard hydroxyapatite/titanium plasma-sprayed cup with the same design. The null hypothesis, which the study aims to reject, is that there is no difference in bone mineral density changes between highly-porous and traditional plasma-sprayed cups. Overall 50 patients will be enrolled to be 1:1 randomized for receiving the investigational cup or the control cup in two centers. Periprosthetic bone mineral density will be measured by DEXA (Dual-Energy X-ray Absorptiometry) around the acetabular cup according to four ROI (Region Of Interest). DEXA scans will be taken at different time-points up to 2-year follow-up. DEXA scan taken before patient discharge will be used as baseline. Patients will be assessed also for clinical and radiological results, with focus on osseointegration signs of the acetabular cup.

Interventions

DEVICEJump System Traser® cup

Press-fit, cementless, 3D-printed, highly-porous trabecular titanium acetabular cup

DEVICEJump System HAX-Pore® cup

Press-fit, cementless, hydroxyapatite/titanium plasma-sprayed acetabular cup

Sponsors

Permedica spa
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Controlled, randomized, unblinded, multicenter

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Patient candidated to undergo unilateral cementless primary total hip arthroplasty with Jump System Traser® cup or Jump System HAX-Pore® cup by Permedica Orthopaedics (study sponsor). * Patient with primary or secondary hip osteoarthritis; * Patient who has given informed consent;

Exclusion criteria

* Male patients younger than 40 years or older than 85 years; * Female patients younger than 50 years or older than 85 years; * Childbearing; * Patients not indicated for receiving the investigational devices; * Patients not indicated for receiving cementless metaphyseal short femoral stems by Permedica Orthopaedics as the Exacta RS or Exacta S brand; * Patients with rheumatoid arthritis, avascular osteonecrosis, severe hip dysplasia (grade III-IV according to Crowe classification), Perthes disease, Paget disease, femoral neck fracture, pelvic fracture or sequelae of previous surgical procedures or trauma to the ipsilateral hip; * Patients with bone disorders; * Patients with diabetes; * Patients under PTH (parathyroid hormone), corticosteroid, or osteoporosis pharmacological therapy; * Patients with disabling disease in the contralateral limb; * Patients with BMI \> 30 or \< 18; * Patients not willing to follow the study protocol; * Patients incapable to understand the study protocol; * Patients addicted to alcohol or drugs; * Patients already enrolled in other clinical investigations;

Design outcomes

Primary

MeasureTime frameDescription
BMD - ROI 1Preoperative, 1 week postoperatively, 3-month, 6-month,12-month, and 24-month follow-upPeriprosthetic BMD (bone mineral density) measured by DEXA in ROI (region of interest) 1 (above the acetabular cup)

Secondary

MeasureTime frameDescription
BMD - ROI 2,3,4Preoperative, 1 week postoperatively, 3-month, 6-month,12-month, and 24-month follow-upPeriprosthetic BMD (bone mineral density) measured by DEXA in ROI (region of interest) 2, 3 and 4 (behind and below the acetabular cup)
Harris hip scorePreoperative,12-month, and 24-month follow-upClinical score for hips undergoing total hip arthroplasty. The Harris hip score ranges from 0 to 100, where 100 indicates the best outcome possible for the patient.
Moore's osseointegration signs12-month and 24-month follow-upFive radiographic signs around the acetabular cup revealing the stability and osseointegration status of cementless component: (1) absence of radiolucent lines; (2) presence of a superolateral buttress; (3) medial stress-shielding; (4) radial trabeculae; and (5) an inferomedial buttress. The presence of 3 to 5 signs visible on anterior-posterior radiograph of the hip indicates 97% probability of a well osseointegrated cup. The presence of 1 or no signs indicates 83% probability of unstable, not osseointegrated cup.

Countries

Italy

Contacts

Primary ContactLorenzo Banci, MSc
lorenzo.banci@permedica.it+390399514811
Backup ContactMarta Colombo, MSc
marta.colombo@permedica.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026